disopyramide has been researched along with Myocardial Infarction in 92 studies
Disopyramide: A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.
disopyramide : A monocarboxylic acid amide that is butanamide substituted by a diisopropylamino group at position 4, a phenyl group at position 2 and a pyridin-2-yl group at position 2. It is used as a anti-arrhythmia drug.
Myocardial Infarction: NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a randomized open study with intravenous lignocaine and disopyramide in patients with suspected acute myocardial infarction and ventricular premature contractions the occurrence of cardiac events, adverse reactions, withdrawals and arrhythmias were compared." | 9.06 | Tolerability and antiarrhythmic efficacy of disopyramide compared to lignocaine in selected patients with suspected acute myocardial infarction. ( Abrahamsen, AM; Gundersen, T; Rønnevik, PK, 1987) |
| "A prospective study evaluated the comparative haemodynamic effects of three Class I antiarrhythmics (lignocaine Class 1B, disopyramide Class 1A and flecainide Class 1C) in 30 patients with uncomplicated acute myocardial infarction." | 9.06 | Comparative haemodynamic effects of intravenous lignocaine, disopyramide and flecainide in uncomplicated acute myocardial infarction. ( Frais, MA; Hafizullah, M; Jackson, NC; Kalra, PA; Reynolds, GW; Silke, B; Taylor, SH; Verma, SP, 1986) |
| "A multi-centre double-blind randomized study is reported in which the effect on mortality of oral disopyramide (300 mg loading dose, then 100 mg qds) was compared with placebo in 1985 patients entering hospital with suspected acute myocardial infarction." | 9.05 | Oral disopyramide after admission to hospital with suspected acute myocardial infarction. U. K. Rythmodan Multicentre Study Group. ( , 1984) |
| "473 patients with suspected acute myocardial infarction were entered into a randomised, double-blind, placebo-controlled comparison of disopyramide phosphate, 150 mg three times a day, and oxprenolol, 40 mg three times a day." | 9.05 | Randomised placebo-controlled trial comparing oxprenolol with disopyramide phosphate in immediate treatment of suspected myocardial infarction. ( Banks, DC; Hampton, JR; Mitchell, JR; Roland, JM; Rowley, JM; Wilcox, RG, 1980) |
| "Patients with acute myocardial infarction admitted to a coronary care unit were given either intravenous and oral disopyramide or matching placebo on admission and throughout their hospital stay." | 9.05 | Intravenous and oral disopyramide after myocardial infarction. ( Barnes, PC; Haybyrne, T; Nicholls, DP, 1980) |
| "The value of beta-blockade and of disopyramide phosphate in the immediate treatment of patients with suspected acute myocardial infarction was assessed in two placebo controlled trials." | 9.05 | Acute intervention studies in patients with myocardial infarction using atenolol, propranolol, oxprenolol and disopyramide phosphate. ( Wilcox, RG, 1981) |
| "1 To evaluate oral disopyramide phosphate in the prophylaxis of dysrhythmias occurring in acute myocardial infarction (MI) patients (presenting within 12 h of symptoms, age 21-70 years), a placebo-controlled, randomized double-blind, in hospital trial was conducted." | 9.05 | A placebo-controlled study to determine the efficacy of oral disopyramide phosphate for the prophylaxis of ventricular dysrhythmias after acute myocardial infarction. ( Cairns, JA; Gent, M; Gupta, RN; Johnson, AL; Johnston, M; Kumana, CR; Rambihar, VS; Tanser, PH; Wildeman, RA, 1982) |
| "Patients with acute myocardial infarction admitted to open wards of three hospitals were given either oral disopyramide (100 mg four times daily) or matching placebo, prophylactically, for seven days." | 9.04 | Oral disopyramide for the prevention of arrhythmias in patients with acute myocardial infarction admitted to open wards. ( Besterman, EM; Carmichael, DJ; Gillham, AD; Griffiths, JW; Kidner, PH; Summers, GD; Zainal, N, 1977) |
| "The effects of intravenously administered disopyramide phosphate were evaluated in seven patients with refractory ventricular tachycardia." | 9.04 | Efficacy of disopyramide phosphate in the treatment of refractory ventricular tachycardia. ( Mason, DT; Miller, RR; Vera, Z; Vismara, LA, 1977) |
| "The incidence of ventricular arrhythmias after myocardial infarction was compared in a double blind study of disopyramide (33 patients), aprindine (34 patients) and placebo (31 patients)." | 9.04 | Effects of disopyramide and aprindine on arrhythmias after acute myocardial infarction. ( Chaudron, JM; Pouleur, H; Reyns, P, 1977) |
| "Twenty-six patients with clinically significant ventricular arrhythmias were randomly assigned to treatment with either intravenous disopyramide or lidocaine; crossover to the other agent was permitted in nine cases of primary drug failure." | 9.04 | Suppression of ventricular arrhythmias with intravenous disopyramide and lidocaine: efficacy comparison in a randomized trial. ( Fozzard, HA; Rawling, DA; Sbarbaro, JA, 1979) |
| "Oral disopyramide given prophylactically following myocardial infarction has been compared with placebo in a double-blind trial using continuous-tape monoriting of the electocardiogram." | 9.04 | Oral disopyramide in prophylaxis of arrhythmias following myocardial infarction. ( Besterman, EM; Jennings, G; Jones, MS; Kidner, PH; Model, DG; Turner, PP, 1976) |
| "The acute tolerability of rapid infusions of bidisomide or disopyramide was evaluated in normal conscious dogs and in conscious dogs 48 h after the creation of myocardial infarctions (MIs)." | 7.68 | Rapid infusions of bidisomide or disopyramide in conscious dogs: effect of myocardial infarction on acute tolerability. ( Frederick, LG; Garthwaite, SM; Schmidt, JJ, 1992) |
| "Intraindividual comparison of the acute response to intravenous quinidine and to intravenous disopyramide was performed in 27 patients with sustained ventricular tachycardia (VT) who underwent serial electrophysiological studies." | 7.67 | Effects of intravenous disopyramide and quinidine on normal myocardium and on the characteristics of arrhythmias: intraindividual comparison in patients with sustained ventricular tachycardia. ( Brachmann, J; Kübler, W; Lengfelder, W; Rizos, I; Schmitt, C; Senges, J; von Olshausen, K, 1987) |
| "In the acute phase of myocardial infarction it is recognized that serum disopyramide concentrations may be lower than expected." | 7.67 | Disopyramide in acute myocardial infarction: problems with changing pharmacokinetics. ( Bryson, SM; Elliott, HL; Thomson, AH, 1986) |
| "To study the effects of acute myocardial infarction on the pharmacokinetics of disopyramide a single oral dose of disopyramide base (200 mg) was administered to 6 patients with myocardial infarction both in the acute (Study I) and recovery (Study II) phases." | 7.67 | Disopyramide pharmacokinetics in patients with acute myocardial infarction. ( Huikuri, H; Jounela, AJ; Pentikäinen, PJ; Wilen, G, 1985) |
| "Disopyramide (2 mg/kg intravenously in 10 minutes) was administered to 14 patients with myocardial infarction within 36 hours of their infarct." | 7.66 | Intravenous disopyramide in myocardial infarction: a haemodynamic study. ( Hill, PD; Marrott, PK; Nairn, PL; Sharman, J; Turner, G, 1983) |
| "The effects of acute myocardial infarction on the pharmacokinetics of disopyramide were studied." | 7.66 | The pharmacokinetics of disopyramide in patients with acute myocardial infarction. ( Jounela, AJ; Oksanen, K; Pentikäinen, PJ, 1982) |
| "1 The haemodynamic and electrocardiographic effects of intravenous disopyramide were studied in fifteen patients with acute myocardial infarction." | 7.66 | Haemodynamic and electrocardiographic effects of intravenous disopyramide (rythmodan) following acute myocardial infarction. ( Davies, GJ; Marrott, PK; Muir, JR, 1979) |
| "Plasma disopyramide concentrations were measured in 19 patients with suspected myocardial infarction (MI) following an oral loading dose of 300 mg." | 7.66 | Plasma disopyramide concentrations following a 300-mg oral loading dose in acute myocardial infarction. ( Hayler, AM; Holt, DW; Matenga, J; Weissberg, PL, 1982) |
| "1 Disopyramide plasma binding was determined in vitro in plasma from 20 patients with acute myocardial infarction (aged 35-79 years) and in 20 age and sex matched healthy subjects." | 7.66 | Prolonged variability in plasma protein binding of disopyramide after acute myocardial infarction. ( David, BM; Ilett, KF; Stenhouse, NS; Whitford, EG, 1983) |
| "This study was performed to investigate the prophylactic effect of disopyramide phosphate on ventricular fibrillation in acute myocardial infarction." | 7.66 | Studies on the preventive method of lowered ventricular fibrillation threshold during experimental acute myocardial infarctions. A comparison between disopyramide phosphate and lidocaine. ( Fukuzaki, H; Hatani, M; Hori, Y; Imai, N; Nadai, T; Okamoto, R; Takano, S; Toh, H, 1981) |
| "The kinetic behavior of disopyramide was studied in 20 patients with suspected myocardial infarction: in 13 of these, the diagnosis was subsequently confirmed." | 7.66 | Disopyramide kinetics in patients with acute myocardial infarction. ( Ilett, KF; Madsen, BW; Woods, JD, 1979) |
| "The electrophysiologic actions of disopyramide phosphate on reentrant ventricular tachycardia induced by premature ventricular stimuli were evaluated in conscious dogs 2 to 4 days after myocardial infarction." | 7.66 | Electrophysiologic effects of disopyramide phosphate on reentrant ventricular arrhythmia in conscious dogs after myocardial infarction. ( Gibson, JK; Lucchesi, BR; Patterson, E, 1980) |
| "A myocardial infarction model in which infarction is the result of an occluding thrombus was used to evaluate the effectiveness of disopyramide phosphate (DP) in abolishing postinfarction ventricular arrhythmis." | 7.65 | Effects of disopyramide phosphate on ventricular arrhythmias in experimental myocardial infarction. ( Kus, T; Sasyniuk, BI, 1976) |
| "Disopyramide was metabolized by the cytochrome enzyme CYP3A4 and clarithromycin competitively inhibits this enzyme, probably resulting in an increase in plasma concentration of disopyramide." | 5.30 | Torsades de pointes ventricular tachycardia induced by clarithromycin and disopyramide in the presence of hypokalemia. ( Hashimoto, T; Hayashi, Y; Ikeda, U; Mitsuhashi, T; Shimada, K; Watanabe, T, 1999) |
| " The suggested dosage regimen of disopyramide seems to result in a satisfactory response." | 5.27 | Kinetics of disopyramide after intravenous infusion to patients with myocardial infarction and heart failure. ( Angelo, HR; Bonde, J; Bødtker, S; Kampmann, JP; Svendsen, TL, 1985) |
| "Disopyramide has a selective effect on potential reentry circuits in ischemic myocardium, and prolongs refractoriness in abnormal myocardium to a greater extent than its effect on the normal ventricle." | 5.27 | Actions of disopyramide on potential reentrant pathways and ventricular tachyarrhythmias in conscious dogs during the late post-myocardial infarction phase. ( Brachmann, J; Cobbe, SM; Hoffmann, E; Kübler, W; Ritzenhoff, A; Senges, J, 1984) |
| "1 Previous pharmacokinetics studies of disopyramide in patients with ischaemic heart disease include unexplained reports of poor bioavailability and extremely long elimination half-lives which undermine accepted dosage recommendations." | 5.26 | Disopyramide pharmacokinetics during recovery from myocardial infarction. ( Bryson, SM; Cairns, CJ; Whiting, B, 1982) |
| "A prospective study evaluated the comparative haemodynamic effects of three Class I antiarrhythmics (lignocaine Class 1B, disopyramide Class 1A and flecainide Class 1C) in 30 patients with uncomplicated acute myocardial infarction." | 5.06 | Comparative haemodynamic effects of intravenous lignocaine, disopyramide and flecainide in uncomplicated acute myocardial infarction. ( Frais, MA; Hafizullah, M; Jackson, NC; Kalra, PA; Reynolds, GW; Silke, B; Taylor, SH; Verma, SP, 1986) |
| "In a randomized open study with intravenous lignocaine and disopyramide in patients with suspected acute myocardial infarction and ventricular premature contractions the occurrence of cardiac events, adverse reactions, withdrawals and arrhythmias were compared." | 5.06 | Tolerability and antiarrhythmic efficacy of disopyramide compared to lignocaine in selected patients with suspected acute myocardial infarction. ( Abrahamsen, AM; Gundersen, T; Rønnevik, PK, 1987) |
| "Patients with acute myocardial infarction admitted to a coronary care unit were given either intravenous and oral disopyramide or matching placebo on admission and throughout their hospital stay." | 5.05 | Intravenous and oral disopyramide after myocardial infarction. ( Barnes, PC; Haybyrne, T; Nicholls, DP, 1980) |
| "The value of beta-blockade and of disopyramide phosphate in the immediate treatment of patients with suspected acute myocardial infarction was assessed in two placebo controlled trials." | 5.05 | Acute intervention studies in patients with myocardial infarction using atenolol, propranolol, oxprenolol and disopyramide phosphate. ( Wilcox, RG, 1981) |
| "A multi-centre double-blind randomized study is reported in which the effect on mortality of oral disopyramide (300 mg loading dose, then 100 mg qds) was compared with placebo in 1985 patients entering hospital with suspected acute myocardial infarction." | 5.05 | Oral disopyramide after admission to hospital with suspected acute myocardial infarction. U. K. Rythmodan Multicentre Study Group. ( , 1984) |
| "473 patients with suspected acute myocardial infarction were entered into a randomised, double-blind, placebo-controlled comparison of disopyramide phosphate, 150 mg three times a day, and oxprenolol, 40 mg three times a day." | 5.05 | Randomised placebo-controlled trial comparing oxprenolol with disopyramide phosphate in immediate treatment of suspected myocardial infarction. ( Banks, DC; Hampton, JR; Mitchell, JR; Roland, JM; Rowley, JM; Wilcox, RG, 1980) |
| "1 To evaluate oral disopyramide phosphate in the prophylaxis of dysrhythmias occurring in acute myocardial infarction (MI) patients (presenting within 12 h of symptoms, age 21-70 years), a placebo-controlled, randomized double-blind, in hospital trial was conducted." | 5.05 | A placebo-controlled study to determine the efficacy of oral disopyramide phosphate for the prophylaxis of ventricular dysrhythmias after acute myocardial infarction. ( Cairns, JA; Gent, M; Gupta, RN; Johnson, AL; Johnston, M; Kumana, CR; Rambihar, VS; Tanser, PH; Wildeman, RA, 1982) |
| "A study was carried out in 33 patients with myocardial infarction and complicating arrhythmias to compare plasma levels of disopyramide attained after administration of conventional capsules or sustained-release tablets." | 5.05 | Plasma levels of disopyramide after administration of conventional capsules and sustained-release tablets. ( Hertzberger, DP; Nauta, IL; van de Calseyde, J, 1983) |
| "The incidence of ventricular arrhythmias after myocardial infarction was compared in a double blind study of disopyramide (33 patients), aprindine (34 patients) and placebo (31 patients)." | 5.04 | Effects of disopyramide and aprindine on arrhythmias after acute myocardial infarction. ( Chaudron, JM; Pouleur, H; Reyns, P, 1977) |
| "Twenty-six patients with clinically significant ventricular arrhythmias were randomly assigned to treatment with either intravenous disopyramide or lidocaine; crossover to the other agent was permitted in nine cases of primary drug failure." | 5.04 | Suppression of ventricular arrhythmias with intravenous disopyramide and lidocaine: efficacy comparison in a randomized trial. ( Fozzard, HA; Rawling, DA; Sbarbaro, JA, 1979) |
| "Oral disopyramide given prophylactically following myocardial infarction has been compared with placebo in a double-blind trial using continuous-tape monoriting of the electocardiogram." | 5.04 | Oral disopyramide in prophylaxis of arrhythmias following myocardial infarction. ( Besterman, EM; Jennings, G; Jones, MS; Kidner, PH; Model, DG; Turner, PP, 1976) |
| "Patients with acute myocardial infarction admitted to open wards of three hospitals were given either oral disopyramide (100 mg four times daily) or matching placebo, prophylactically, for seven days." | 5.04 | Oral disopyramide for the prevention of arrhythmias in patients with acute myocardial infarction admitted to open wards. ( Besterman, EM; Carmichael, DJ; Gillham, AD; Griffiths, JW; Kidner, PH; Summers, GD; Zainal, N, 1977) |
| "The effects of intravenously administered disopyramide phosphate were evaluated in seven patients with refractory ventricular tachycardia." | 5.04 | Efficacy of disopyramide phosphate in the treatment of refractory ventricular tachycardia. ( Mason, DT; Miller, RR; Vera, Z; Vismara, LA, 1977) |
| "To study influence of congestive heart failure (CHF) and acute myocardial infarction (AMI) on alpha 1-acid glycoprotein (AGP) and sialic acid (SA) concentration, and binding of AGP to disopyramide (Dis)." | 3.69 | Serum alpha 1-acid glycoprotein, sialic acid, and protein binding of disopyramide in normal subjects and cardiac patients. ( Chu, JS; Kishion, S; Miyazaki, K; Nomura, A, 1997) |
| "In order to study the effects of treatment with class 1 antiarrhythmics on the metabolic, hemodynamic, and electrocardiographic responses to adrenaline, 12 healthy volunteers were infused on four occasions, after pretreatment with placebo, disopyramide, mexiletine, and flecainide, respectively, with adrenaline at a rate producing serum adrenaline concentrations comparable with those seen in acute myocardial infarction." | 3.68 | Metabolic, hemodynamic, and electrocardiographic responses to increased circulating adrenaline: effects of pretreatment with class 1 antiarrhythmics. ( Gullberg, B; Hansen, O; Johansson, BW, 1991) |
| "The inotropic effect of a per os single dose of 200 mg disopyramide phosphate was studied in 25 patients during the second week after acute myocardial infarction with no signs of heart failure." | 3.68 | Mechanographic assessment of disopyramide in postinfarction patients. ( Giannakoulis, IL; Gitsios, C; Kanonidis, IE; Kokkas, V; Papadopoulos, CL; Papayiannis, J; Sakadamis, GC, 1991) |
| "The acute tolerability of rapid infusions of bidisomide or disopyramide was evaluated in normal conscious dogs and in conscious dogs 48 h after the creation of myocardial infarctions (MIs)." | 3.68 | Rapid infusions of bidisomide or disopyramide in conscious dogs: effect of myocardial infarction on acute tolerability. ( Frederick, LG; Garthwaite, SM; Schmidt, JJ, 1992) |
| "Intraindividual comparison of the acute response to intravenous quinidine and to intravenous disopyramide was performed in 27 patients with sustained ventricular tachycardia (VT) who underwent serial electrophysiological studies." | 3.67 | Effects of intravenous disopyramide and quinidine on normal myocardium and on the characteristics of arrhythmias: intraindividual comparison in patients with sustained ventricular tachycardia. ( Brachmann, J; Kübler, W; Lengfelder, W; Rizos, I; Schmitt, C; Senges, J; von Olshausen, K, 1987) |
| "In the acute phase of myocardial infarction it is recognized that serum disopyramide concentrations may be lower than expected." | 3.67 | Disopyramide in acute myocardial infarction: problems with changing pharmacokinetics. ( Bryson, SM; Elliott, HL; Thomson, AH, 1986) |
| "To study the effects of acute myocardial infarction on the pharmacokinetics of disopyramide a single oral dose of disopyramide base (200 mg) was administered to 6 patients with myocardial infarction both in the acute (Study I) and recovery (Study II) phases." | 3.67 | Disopyramide pharmacokinetics in patients with acute myocardial infarction. ( Huikuri, H; Jounela, AJ; Pentikäinen, PJ; Wilen, G, 1985) |
| "The kinetic behavior of disopyramide was studied in 20 patients with suspected myocardial infarction: in 13 of these, the diagnosis was subsequently confirmed." | 3.66 | Disopyramide kinetics in patients with acute myocardial infarction. ( Ilett, KF; Madsen, BW; Woods, JD, 1979) |
| "Three hundred fifty-eight of 429 (83%) consecutive patients with acute myocardial infarction (MI) and a normal PR interval received various antiarrhythmic drugs (AD), including lidocaine and/or procainamide, quinidine, digoxin, propranolol or disopyramide." | 3.66 | Effects of antiarrhythmic drugs on atrioventricular conduction in patients with acute myocardial infarction. ( Abbott, JA; Cheitlin, MD; Desai, J; Holford, N; Peters, RW; Remedios, P; Scheinman, MM, 1980) |
| "This study was performed to investigate the prophylactic effect of disopyramide phosphate on ventricular fibrillation in acute myocardial infarction." | 3.66 | Studies on the preventive method of lowered ventricular fibrillation threshold during experimental acute myocardial infarctions. A comparison between disopyramide phosphate and lidocaine. ( Fukuzaki, H; Hatani, M; Hori, Y; Imai, N; Nadai, T; Okamoto, R; Takano, S; Toh, H, 1981) |
| " disopyramide for a supraventricular tachycardia resulted in a more serious ventricular dysrhythmia giving hypotension and this probably contributed to the development of a myocardial infarction." | 3.66 | Adverse reaction to disopyramide. ( Dibble, JB; Webster, NR, 1979) |
| "1 The haemodynamic and electrocardiographic effects of intravenous disopyramide were studied in fifteen patients with acute myocardial infarction." | 3.66 | Haemodynamic and electrocardiographic effects of intravenous disopyramide (rythmodan) following acute myocardial infarction. ( Davies, GJ; Marrott, PK; Muir, JR, 1979) |
| "Plasma disopyramide concentrations were measured in 19 patients with suspected myocardial infarction (MI) following an oral loading dose of 300 mg." | 3.66 | Plasma disopyramide concentrations following a 300-mg oral loading dose in acute myocardial infarction. ( Hayler, AM; Holt, DW; Matenga, J; Weissberg, PL, 1982) |
| "The effects of acute myocardial infarction on the pharmacokinetics of disopyramide were studied." | 3.66 | The pharmacokinetics of disopyramide in patients with acute myocardial infarction. ( Jounela, AJ; Oksanen, K; Pentikäinen, PJ, 1982) |
| "1 Disopyramide plasma binding was determined in vitro in plasma from 20 patients with acute myocardial infarction (aged 35-79 years) and in 20 age and sex matched healthy subjects." | 3.66 | Prolonged variability in plasma protein binding of disopyramide after acute myocardial infarction. ( David, BM; Ilett, KF; Stenhouse, NS; Whitford, EG, 1983) |
| "Disopyramide (2 mg/kg intravenously in 10 minutes) was administered to 14 patients with myocardial infarction within 36 hours of their infarct." | 3.66 | Intravenous disopyramide in myocardial infarction: a haemodynamic study. ( Hill, PD; Marrott, PK; Nairn, PL; Sharman, J; Turner, G, 1983) |
| "The electrophysiologic actions of disopyramide phosphate on reentrant ventricular tachycardia induced by premature ventricular stimuli were evaluated in conscious dogs 2 to 4 days after myocardial infarction." | 3.66 | Electrophysiologic effects of disopyramide phosphate on reentrant ventricular arrhythmia in conscious dogs after myocardial infarction. ( Gibson, JK; Lucchesi, BR; Patterson, E, 1980) |
| "A myocardial infarction model in which infarction is the result of an occluding thrombus was used to evaluate the effectiveness of disopyramide phosphate (DP) in abolishing postinfarction ventricular arrhythmis." | 3.65 | Effects of disopyramide phosphate on ventricular arrhythmias in experimental myocardial infarction. ( Kus, T; Sasyniuk, BI, 1976) |
| "Disopyramide was metabolized by the cytochrome enzyme CYP3A4 and clarithromycin competitively inhibits this enzyme, probably resulting in an increase in plasma concentration of disopyramide." | 1.30 | Torsades de pointes ventricular tachycardia induced by clarithromycin and disopyramide in the presence of hypokalemia. ( Hashimoto, T; Hayashi, Y; Ikeda, U; Mitsuhashi, T; Shimada, K; Watanabe, T, 1999) |
| "Disopyramide has a selective effect on potential reentry circuits in ischemic myocardium, and prolongs refractoriness in abnormal myocardium to a greater extent than its effect on the normal ventricle." | 1.27 | Actions of disopyramide on potential reentrant pathways and ventricular tachyarrhythmias in conscious dogs during the late post-myocardial infarction phase. ( Brachmann, J; Cobbe, SM; Hoffmann, E; Kübler, W; Ritzenhoff, A; Senges, J, 1984) |
| " The suggested dosage regimen of disopyramide seems to result in a satisfactory response." | 1.27 | Kinetics of disopyramide after intravenous infusion to patients with myocardial infarction and heart failure. ( Angelo, HR; Bonde, J; Bødtker, S; Kampmann, JP; Svendsen, TL, 1985) |
| "Disopyramide was only modestly active, while flecainide and encainide had the least favorable profiles of effect in suppressing re-entry arrhythmias in this model." | 1.27 | Assessment of drug effects on spontaneous and induced ventricular arrhythmias in a 24-h canine infarction model. ( Gomoll, AW, 1987) |
| "1 Previous pharmacokinetics studies of disopyramide in patients with ischaemic heart disease include unexplained reports of poor bioavailability and extremely long elimination half-lives which undermine accepted dosage recommendations." | 1.26 | Disopyramide pharmacokinetics during recovery from myocardial infarction. ( Bryson, SM; Cairns, CJ; Whiting, B, 1982) |
| "Disopyramide was administered in a bolus dose of 2 mg/kg over 10 min with an optional second bolus of 1 mg/kg and infusion of 0." | 1.26 | The antiarrhythmic effect of intravenous disopyramide in an open study. ( Bett, JH; Donnelly, GL; Heddle, WF; Kemp, RJ; Manolas, E; Nelson, GI; Sloman, JG; Tonkin, AM, 1982) |
| "Symptomatic ventricular arrhythmias require treatment, whereas benign simple ventricular ectopy does not; however, the treatment of asymptomatic high-grade ventricular ectopy remains controversial." | 1.26 | Ventricular ectopy: etiology, evaluation, and therapy. ( Reid, PR; Vlay, SC, 1982) |
| "Disopyramide has the advantage of being available both as an oral and an intravenous preparation and is a useful drug to be added to the list of more conventional anti-dysrhythmic agents." | 1.26 | Disopyramide--an effective treatment for lignocaine resistant ventricular dysrhythmias. ( Green, AG, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 78 (84.78) | 18.7374 |
| 1990's | 13 (14.13) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (1.09) | 2.80 |
| Authors | Studies |
|---|---|
| Johnson, RE | 1 |
| Baizman, ER | 1 |
| Becker, C | 1 |
| Bohnet, EA | 1 |
| Bell, RH | 1 |
| Birsner, NC | 1 |
| Busacca, CA | 1 |
| Carabateas, PM | 1 |
| Chadwick, CC | 1 |
| Gruett, MD | 1 |
| Vlok, N | 1 |
| Hedding, KA | 1 |
| Van Dyk, MA | 1 |
| Wilcox, RG | 2 |
| Rowley, JM | 1 |
| Hampton, JR | 2 |
| Mitchell, JR | 1 |
| Roland, JM | 1 |
| Banks, DC | 1 |
| Nicholls, DP | 1 |
| Haybyrne, T | 1 |
| Barnes, PC | 1 |
| Vlay, SC | 1 |
| Reid, PR | 1 |
| Theisen, K | 2 |
| Jahrmärker, H | 1 |
| Sharma, BD | 1 |
| Chug, S | 1 |
| Mathur, KP | 1 |
| Nigam, P | 1 |
| Khan, S | 1 |
| Singh, R | 1 |
| Kapoor, KK | 1 |
| Kumar, A | 1 |
| Gupta, AK | 1 |
| Allen-Narker, RA | 1 |
| Roberts, CJ | 1 |
| Marshall, AJ | 1 |
| Jordan, SC | 1 |
| Barritt, DW | 1 |
| Goodfellow, RM | 1 |
| Marrott, PK | 2 |
| Nairn, PL | 1 |
| Hill, PD | 1 |
| Turner, G | 1 |
| Sharman, J | 1 |
| Nauta, IL | 1 |
| van de Calseyde, J | 1 |
| Hertzberger, DP | 1 |
| Nishino, T | 1 |
| Yasuda, H | 1 |
| Cobbe, SM | 1 |
| Hoffmann, E | 1 |
| Ritzenhoff, A | 1 |
| Brachmann, J | 3 |
| Kübler, W | 2 |
| Senges, J | 3 |
| Kumana, CR | 2 |
| Rambihar, VS | 2 |
| Tanser, PH | 2 |
| Cairns, JA | 2 |
| Gupta, RN | 2 |
| Wildeman, RA | 2 |
| Johnston, M | 2 |
| Johnson, AL | 2 |
| Gent, M | 2 |
| Willis, K | 1 |
| Yanaga, T | 1 |
| Ichimaru, Y | 1 |
| Ueno, T | 1 |
| Hata, Y | 1 |
| Okamoto, K | 1 |
| Kodama, Y | 1 |
| Otsuka, K | 1 |
| David, BM | 2 |
| Ilett, KF | 3 |
| Whitford, EG | 1 |
| Stenhouse, NS | 1 |
| Tonkin, AM | 1 |
| Heddle, WF | 1 |
| Bett, JH | 1 |
| Kemp, RJ | 1 |
| Donnelly, GL | 1 |
| Nelson, GI | 1 |
| Manolas, E | 1 |
| Sloman, JG | 2 |
| Hillson, RM | 1 |
| Boyd, E | 1 |
| Cunningham, J | 1 |
| Bryson, SM | 2 |
| Cairns, CJ | 1 |
| Whiting, B | 1 |
| Jounela, AJ | 2 |
| Pentikäinen, PJ | 2 |
| Oksanen, K | 1 |
| Weissberg, PL | 1 |
| Matenga, J | 1 |
| Hayler, AM | 1 |
| Holt, DW | 1 |
| Bassan, R | 1 |
| Miqueloti, P | 1 |
| de Souza, MA | 1 |
| Luz, FS | 1 |
| Desai, JM | 1 |
| Scheinman, MM | 2 |
| Hirschfeld, D | 1 |
| Gonzalez, R | 1 |
| Peters, RW | 2 |
| Hori, Y | 1 |
| Okamoto, R | 1 |
| Hatani, M | 1 |
| Imai, N | 1 |
| Toh, H | 1 |
| Takano, S | 1 |
| Nadai, T | 1 |
| Fukuzaki, H | 1 |
| Remedios, P | 1 |
| Cheitlin, MD | 1 |
| Holford, N | 1 |
| Desai, J | 1 |
| Abbott, JA | 1 |
| Madsen, BW | 2 |
| Patterson, E | 1 |
| Gibson, JK | 1 |
| Lucchesi, BR | 1 |
| Ogawa, S | 1 |
| Mitamura, H | 1 |
| Katoh, H | 1 |
| Hayashi, Y | 1 |
| Ikeda, U | 1 |
| Hashimoto, T | 1 |
| Watanabe, T | 1 |
| Mitsuhashi, T | 1 |
| Shimada, K | 1 |
| Chu, JS | 1 |
| Kishion, S | 1 |
| Nomura, A | 1 |
| Miyazaki, K | 1 |
| Jennings, G | 2 |
| Jones, MS | 1 |
| Besterman, EM | 4 |
| Model, DG | 1 |
| Turner, PP | 1 |
| Kidner, PH | 6 |
| Ward, JW | 2 |
| Zainal, N | 2 |
| Carmichael, DJ | 2 |
| Griffiths, JW | 1 |
| Gillham, AD | 1 |
| Summers, GD | 1 |
| Ross, D | 1 |
| Vohra, J | 1 |
| Green, AG | 1 |
| Vismara, LA | 1 |
| Vera, Z | 1 |
| Miller, RR | 1 |
| Mason, DT | 1 |
| Pouleur, H | 1 |
| Chaudron, JM | 1 |
| Reyns, P | 1 |
| Koch-Weser, J | 2 |
| Woods, JD | 1 |
| Sbarbaro, JA | 1 |
| Rawling, DA | 1 |
| Fozzard, HA | 1 |
| Dibble, JB | 1 |
| Webster, NR | 1 |
| Goldman, P | 1 |
| Ingelfinger, JA | 1 |
| Davies, GJ | 1 |
| Muir, JR | 1 |
| Jones, B | 1 |
| Model, D | 1 |
| Turner, P | 1 |
| Harner, RH | 1 |
| Boyd, RB | 1 |
| Boland, J | 1 |
| Lisin, N | 1 |
| Marcelle, R | 1 |
| Carlier, J | 1 |
| Sasyniuk, BI | 2 |
| Kus, T | 2 |
| Kinghorn, GR | 1 |
| Hillis, WS | 1 |
| Tweddel, A | 1 |
| Lorimer, AR | 1 |
| Lawrie, TD | 1 |
| Dean, RR | 1 |
| Schmidt, JJ | 1 |
| Frederick, LG | 1 |
| Garthwaite, SM | 1 |
| He, ZS | 1 |
| Komori, S | 1 |
| Tamura, K | 1 |
| Hashimoto, K | 1 |
| Tanabe, T | 1 |
| Takahashi, K | 1 |
| Yoshioka, K | 1 |
| Goto, Y | 1 |
| Hansen, O | 1 |
| Johansson, BW | 1 |
| Gullberg, B | 1 |
| Sakadamis, GC | 1 |
| Papadopoulos, CL | 1 |
| Kanonidis, IE | 1 |
| Papayiannis, J | 1 |
| Giannakoulis, IL | 1 |
| Gitsios, C | 1 |
| Kokkas, V | 1 |
| Campbell, JK | 1 |
| Marshall, RJ | 1 |
| Winslow, E | 1 |
| Hashimoto, H | 1 |
| Satoh, N | 1 |
| Nakashima, M | 1 |
| Belpaire, FM | 1 |
| Bogaert, MG | 1 |
| Hoffmeister, HM | 1 |
| Hörmann, HP | 1 |
| Beyer, M | 1 |
| Seipel, L | 1 |
| Roden, DM | 1 |
| Podrid, PJ | 1 |
| Aizawa, Y | 1 |
| Funazaki, T | 1 |
| Satoh, M | 1 |
| Suzuki, K | 1 |
| Aizawa, M | 1 |
| Shibata, A | 1 |
| Rønnevik, PK | 1 |
| Gundersen, T | 1 |
| Abrahamsen, AM | 1 |
| Gao, TL | 1 |
| Wood, M | 1 |
| Silke, B | 1 |
| Frais, MA | 1 |
| Verma, SP | 1 |
| Reynolds, GW | 1 |
| Hafizullah, M | 1 |
| Kalra, PA | 1 |
| Jackson, NC | 1 |
| Taylor, SH | 1 |
| Gomoll, AW | 1 |
| Goedel-Meinen, L | 1 |
| Hofmann, M | 1 |
| Schmidt, G | 1 |
| Barthel, P | 1 |
| Baedeker, W | 1 |
| Blömer, H | 1 |
| Denniss, AR | 1 |
| Ross, DL | 1 |
| Cody, DV | 1 |
| Russell, PA | 1 |
| Young, AA | 1 |
| Richards, DA | 1 |
| Uther, JB | 1 |
| Zannad, F | 1 |
| Royer-Morrot, MJ | 1 |
| Zakari, I | 1 |
| Sadoul, N | 1 |
| Royer, RJ | 1 |
| Pedersen-Bjergaard, O | 1 |
| Lindeneg, O | 1 |
| Svendsen, TL | 3 |
| Enk, B | 1 |
| Fridberg, M | 1 |
| Rizos, I | 1 |
| Lengfelder, W | 1 |
| Schmitt, C | 1 |
| von Olshausen, K | 1 |
| Bonde, J | 2 |
| Pedersen, LE | 1 |
| Angelo, HR | 2 |
| Trap-Jensen, J | 1 |
| Graudal, NA | 1 |
| Kampmann, JP | 2 |
| Elliott, HL | 1 |
| Thomson, AH | 1 |
| Härtel, G | 1 |
| Kasanuki, H | 1 |
| Onishi, S | 1 |
| Hirosawa, K | 1 |
| Huikuri, H | 1 |
| Wilen, G | 1 |
| Caplin, JL | 1 |
| Johnston, A | 1 |
| Hamer, J | 1 |
| Camm, AJ | 1 |
| Bødtker, S | 1 |
6 reviews available for disopyramide and Myocardial Infarction
| Article | Year |
|---|---|
[Medical treatment of extrasystole and tachycardia (author's transl)].
Topics: Action Potentials; Ajmaline; Amiodarone; Anti-Arrhythmia Agents; Bretylium Compounds; Calcium; Cardi | 1980 |
Presentation and analysis of the results of clinical trials in cardiovascular disease.
Topics: Aspirin; Clinical Trials as Topic; Disopyramide; Home Care Services; Hospitalization; Humans; Myocar | 1981 |
Prevention of sudden coronary death by chronic antiarrhythmic therapy.
Topics: Amiodarone; Anti-Arrhythmia Agents; Aprindine; Bretylium Compounds; Clinical Trials as Topic; Death, | 1978 |
The role of antiarrhythmic drugs in prevention of sudden cardiac death.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Aprindine; Arrhythmias, Cardiac; Cardiac Comple | 1985 |
Plasma drug binding: implications for anesthesiologists.
Topics: Age Factors; Alfentanil; Alprenolol; Anesthesia; Anesthetics; Blood Proteins; Bupivacaine; Burns; Ca | 1986 |
[Disopyramide: its mechanisms of action and clinical use].
Topics: Action Potentials; Animals; Arrhythmias, Cardiac; Coronary Disease; Disopyramide; Drug Evaluation; D | 1985 |
28 trials available for disopyramide and Myocardial Infarction
| Article | Year |
|---|---|
Randomised placebo-controlled trial comparing oxprenolol with disopyramide phosphate in immediate treatment of suspected myocardial infarction.
Topics: Acute Disease; Adult; Aged; Arrhythmias, Cardiac; Blood Pressure; Clinical Trials as Topic; Disopyra | 1980 |
Intravenous and oral disopyramide after myocardial infarction.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Arrhythmias, Cardiac; Clinical Trials as Topic; Di | 1980 |
Acute intervention studies in patients with myocardial infarction using atenolol, propranolol, oxprenolol and disopyramide phosphate.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Clinical Trials as Topic; Disopyramide; Double-B | 1981 |
Effect of oral disopyramide on mortality and extension of infarction in cases of acute myocardial infarction admitted to open wards.
Topics: Administration, Oral; Aged; Arrhythmias, Cardiac; Clinical Trials as Topic; Disopyramide; Electrocar | 1983 |
Oral disopyramide after admission to hospital with suspected acute myocardial infarction. U. K. Rythmodan Multicentre Study Group.
Topics: Clinical Trials as Topic; Disopyramide; Double-Blind Method; Female; Hospitalization; Humans; Male; | 1984 |
Chemoprophylaxis of arrhythmias with oral disopyramide in acute myocardial infarction.
Topics: Administration, Oral; Adult; Aged; Arrhythmias, Cardiac; Clinical Trials as Topic; Disopyramide; Fem | 1983 |
Prophylaxis against ventricular arrhythmias in suspected acute myocardial infarction: a comparison of tocainide and disopyramide.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disopyramide; Female; Humans; Lidocaine; Male; Middle | 1984 |
Plasma levels of disopyramide after administration of conventional capsules and sustained-release tablets.
Topics: Adult; Aged; Arrhythmias, Cardiac; Capsules; Delayed-Action Preparations; Disopyramide; Double-Blind | 1983 |
A placebo-controlled study to determine the efficacy of oral disopyramide phosphate for the prophylaxis of ventricular dysrhythmias after acute myocardial infarction.
Topics: Adult; Aged; Arrhythmias, Cardiac; Clinical Trials as Topic; Disopyramide; Double-Blind Method; Fema | 1982 |
Absorption and antidysrhythmic activity of oral disopyramide phosphate after acute myocardial infarction.
Topics: Adult; Aged; Arrhythmias, Cardiac; Body Weight; Clinical Trials as Topic; Disopyramide; Double-Blind | 1982 |
Prophylactic disopysramide: its clinical effects related to plasma concentration in myocardial infarction.
Topics: Adult; Aged; Arrhythmias, Cardiac; Clinical Trials as Topic; Disopyramide; Double-Blind Method; Fema | 1980 |
Oral disopyramide in prophylaxis of arrhythmias following myocardial infarction.
Topics: Administration, Oral; Arrhythmias, Cardiac; Atrial Fibrillation; Clinical Trials as Topic; Disopyram | 1976 |
Arrhythmia prevention in early myocardial infarction.
Topics: Administration, Oral; Arrhythmias, Cardiac; Clinical Trials as Topic; Disopyramide; Drug Therapy, Co | 1977 |
Oral disopyramide for the prevention of arrhythmias in patients with acute myocardial infarction admitted to open wards.
Topics: Acute Disease; Administration, Oral; Aged; Arrhythmias, Cardiac; Clinical Trials as Topic; Disopyram | 1977 |
Anti-dysrhythmic treatment in acute myocardial infarction.
Topics: Acute Disease; Administration, Oral; Atenolol; Clinical Trials as Topic; Disopyramide; Double-Blind | 1979 |
Efficacy of disopyramide phosphate in the treatment of refractory ventricular tachycardia.
Topics: Aged; Clinical Trials as Topic; Coronary Disease; Disopyramide; Drug Evaluation; Heart Failure; Huma | 1977 |
Effects of disopyramide and aprindine on arrhythmias after acute myocardial infarction.
Topics: Acute Disease; Adult; Aged; Aprindine; Arrhythmias, Cardiac; Clinical Trials as Topic; Disopyramide; | 1977 |
Prevention of sudden coronary death by chronic antiarrhythmic therapy.
Topics: Amiodarone; Anti-Arrhythmia Agents; Aprindine; Bretylium Compounds; Clinical Trials as Topic; Death, | 1978 |
Suppression of ventricular arrhythmias with intravenous disopyramide and lidocaine: efficacy comparison in a randomized trial.
Topics: Acute Disease; Adult; Aged; Arrhythmias, Cardiac; Coronary Disease; Disopyramide; Humans; Injections | 1979 |
Disopyramide in the treatment and prevention of arrhythmias following myocardial infarction.
Topics: Arrhythmias, Cardiac; Clinical Trials as Topic; Disopyramide; Humans; Myocardial Infarction; Pyridin | 1976 |
Evaluation of disopyramide and mexiletine used alone and in combination for ventricular arrhythmias in patients with and without overt heart disease.
Topics: Administration, Oral; Adult; Aged; Cardiac Complexes, Premature; Cardiomyopathy, Dilated; Cardiomyop | 1991 |
The role of antiarrhythmic drugs in prevention of sudden cardiac death.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Aprindine; Arrhythmias, Cardiac; Cardiac Comple | 1985 |
Tolerability and antiarrhythmic efficacy of disopyramide compared to lignocaine in selected patients with suspected acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Arrhythmias, Cardiac; Disopyramide; Drug Therapy, Combination; Fe | 1987 |
Comparative haemodynamic effects of intravenous lignocaine, disopyramide and flecainide in uncomplicated acute myocardial infarction.
Topics: Adult; Aged; Disopyramide; Flecainide; Hemodynamics; Humans; Infusions, Intravenous; Lidocaine; Male | 1986 |
[Effect of class I anti-arrhythmia agents on the signal-averaged ECG].
Topics: Anti-Arrhythmia Agents; Cardiomyopathy, Dilated; Clinical Trials as Topic; Coronary Disease; Disopyr | 1988 |
Randomized controlled trial of prophylactic antiarrhythmic therapy in patients with inducible ventricular tachyarrhythmias after recent myocardial infarction.
Topics: Actuarial Analysis; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disopyramide; Electric Stimu | 1988 |
[Disopyramide and lignocaine in the treatment of ventricular arrhythmia in patients with acute ischemic heart disease].
Topics: Aged; Arrhythmias, Cardiac; Clinical Trials as Topic; Coronary Disease; Disopyramide; Double-Blind M | 1986 |
Haemodynamic effects of disopyramide using a new model of intravenous administration.
Topics: Disopyramide; Hemodynamics; Humans; Injections, Intravenous; Kinetics; Male; Models, Biological; Myo | 1987 |
60 other studies available for disopyramide and Myocardial Infarction
| Article | Year |
|---|---|
4,5-Dihydro-1-phenyl-1H-2,4-benzodiazepines: novel antiarrhythmic agents.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzodiazepines; Cats; Disease Models, Animal | 1993 |
Saved by the pump: Two successful resuscitations utilising emergency department-initiated extracorporeal cardiopulmonary resuscitation in South Africa.
Topics: Anti-Arrhythmia Agents; Cardiopulmonary Resuscitation; Cardiotoxicity; Disopyramide; Extracorporeal | 2021 |
Ventricular ectopy: etiology, evaluation, and therapy.
Topics: Adrenergic beta-Antagonists; Amiodarone; Angina Pectoris; Anti-Arrhythmia Agents; Aprindine; Arrhyth | 1982 |
Intravenous disopyramide in myocardial infarction: a haemodynamic study.
Topics: Adult; Aged; Blood Pressure; Disopyramide; Female; Heart Rate; Hemodynamics; Humans; Infusions, Pare | 1983 |
[Disopyramide, an anti-arrhythmia agent for acute stage of myocardial infarct].
Topics: Anti-Arrhythmia Agents; Disopyramide; Humans; Myocardial Infarction | 1983 |
Actions of disopyramide on potential reentrant pathways and ventricular tachyarrhythmias in conscious dogs during the late post-myocardial infarction phase.
Topics: Animals; Cardiac Pacing, Artificial; Disopyramide; Dogs; Electrocardiography; Electrodes; Infusions, | 1984 |
The usefulness of Holter monitoring in the evaluation of antiarrhythmic drug efficacy for tachycardia.
Topics: Adult; Aged; Angina Pectoris, Variant; Anti-Arrhythmia Agents; Diltiazem; Disopyramide; Female; Hear | 1983 |
Prolonged variability in plasma protein binding of disopyramide after acute myocardial infarction.
Topics: Adult; Aged; Disopyramide; Dose-Response Relationship, Drug; Electrocardiography; Female; Humans; In | 1983 |
The antiarrhythmic effect of intravenous disopyramide in an open study.
Topics: Adolescent; Adult; Aged; Arrhythmias, Cardiac; Coronary Care Units; Disopyramide; Drug Evaluation; F | 1982 |
Disopyramide pharmacokinetics during recovery from myocardial infarction.
Topics: Adult; Aged; Biological Availability; Coronary Disease; Disopyramide; Female; Half-Life; Humans; Kin | 1982 |
The pharmacokinetics of disopyramide in patients with acute myocardial infarction.
Topics: Adult; Aged; Disopyramide; Female; Half-Life; Humans; Intestinal Absorption; Kinetics; Male; Middle | 1982 |
Plasma disopyramide concentrations following a 300-mg oral loading dose in acute myocardial infarction.
Topics: Adult; Aged; Aspartate Aminotransferases; Disopyramide; Female; Humans; Male; Middle Aged; Myocardia | 1982 |
[Hemodynamic effects of oral disopyramide in patients with acute myocardial infarction].
Topics: Adult; Aged; Arrhythmias, Cardiac; Blood Pressure; Disopyramide; Female; Heart Rate; Humans; Male; M | 1982 |
Cardiovascular collapse associated with disopyramide therapy.
Topics: Administration, Oral; Aged; Arrhythmias, Cardiac; Disopyramide; Electrocardiography; Female; Heart A | 1981 |
Studies on the preventive method of lowered ventricular fibrillation threshold during experimental acute myocardial infarctions. A comparison between disopyramide phosphate and lidocaine.
Topics: Animals; Disease Models, Animal; Disopyramide; Dogs; Dose-Response Relationship, Drug; Injections, I | 1981 |
Effects of antiarrhythmic drugs on atrioventricular conduction in patients with acute myocardial infarction.
Topics: Aged; Anti-Arrhythmia Agents; Bundle-Branch Block; Digoxin; Disopyramide; Heart Block; Heart Conduct | 1980 |
Plasma binding of disopyramide.
Topics: Blood Proteins; Disopyramide; Heart Diseases; Humans; Kinetics; Myocardial Infarction; Protein Bindi | 1980 |
Electrophysiologic effects of disopyramide phosphate on reentrant ventricular arrhythmia in conscious dogs after myocardial infarction.
Topics: Animals; Arrhythmias, Cardiac; Disopyramide; Dogs; Electrophysiology; Heart Conduction System; Heart | 1980 |
Effect of E-4031, a new class III antiarrhythmic drug, on reentrant ventricular arrhythmias: comparison with conventional class I drugs.
Topics: Animals; Anti-Arrhythmia Agents; Aprindine; Arrhythmias, Cardiac; Disease Models, Animal; Disopyrami | 1993 |
Torsades de pointes ventricular tachycardia induced by clarithromycin and disopyramide in the presence of hypokalemia.
Topics: Aged; Anti-Arrhythmia Agents; Anti-Bacterial Agents; Arrhythmias, Cardiac; Clarithromycin; Cytochrom | 1999 |
Serum alpha 1-acid glycoprotein, sialic acid, and protein binding of disopyramide in normal subjects and cardiac patients.
Topics: Adult; Aged; Disopyramide; Female; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction; | 1997 |
[Drug therapy of tachyarrhythmias (author's transl)].
Topics: Action Potentials; Adrenergic beta-Antagonists; Ajmaline; Amiodarone; Anti-Arrhythmia Agents; Aprind | 1978 |
Disopyramide in myocardial infarction.
Topics: Aged; Arrhythmias, Cardiac; Disopyramide; Drug Evaluation; Humans; Middle Aged; Myocardial Infarctio | 1977 |
Disopyramide in myocardial infarction.
Topics: Depression, Chemical; Disopyramide; Heart Block; Heart Conduction System; Humans; Hypotension; Myoca | 1978 |
Disopyramide in myocardial infarction.
Topics: Arrhythmias, Cardiac; Disopyramide; Humans; Myocardial Infarction; Pyridines | 1978 |
Disopyramide--an effective treatment for lignocaine resistant ventricular dysrhythmias.
Topics: Arrhythmias, Cardiac; Cardiac Complexes, Premature; Disopyramide; Female; Humans; Lidocaine; Male; M | 1979 |
Disopyramide.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Chemical Phenomena; Chemistry; Disopyramide; Heart; He | 1979 |
Disopyramide kinetics in patients with acute myocardial infarction.
Topics: Administration, Oral; Aged; Disopyramide; Dose-Response Relationship, Drug; Drug Administration Sche | 1979 |
Adverse reaction to disopyramide.
Topics: Arrhythmias, Cardiac; Disopyramide; Electrocardiography; Female; Humans; Hypotension; Injections, In | 1979 |
Therapy with antiarrhythmic drugs.
Topics: Acetylation; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disopyramide; Heart Failure; Humans; Indo | 1978 |
Oral disopyramide in the prevention of ventricular arrhythmias following myocardial infarction in patients managed on the coronary care unit and open ward.
Topics: Administration, Oral; Adult; Aged; Arrhythmias, Cardiac; Coronary Care Units; Disopyramide; Female; | 1978 |
Haemodynamic and electrocardiographic effects of intravenous disopyramide (rythmodan) following acute myocardial infarction.
Topics: Adult; Blood Pressure; Cardiac Output; Disopyramide; Electrocardiography; Female; Heart Rate; Hemody | 1979 |
Resistant ventricular tachycardias and recurrent cardiac arrests. 96 episodes.
Topics: Aged; Disopyramide; Electric Countershock; Heart Aneurysm; Humans; Male; Myocardial Infarction; Prop | 1977 |
Prevention of ventricular arrhythmias after myocardial infarction.
Topics: Disopyramide; Humans; Lidocaine; Mexiletine; Myocardial Infarction; Procainamide; Propranolol; Quini | 1977 |
[Effect of intravenous disopyramide on the hemodynamics of patients hospitalized in intensive care units].
Topics: Adult; Aged; Blood Pressure; Cardiac Output; Disopyramide; Female; Heart Rate; Hemodynamics; Humans; | 1976 |
Cellular electrophysiologic changes induced by disopyramide phosphate in normal infarcted hearts.
Topics: Action Potentials; Animals; Disopyramide; Dogs; Heart Conduction System; In Vitro Techniques; Myocar | 1976 |
The pharmacokinetics of disopyramide following myocardial infarction with special reference to oral and intravenous dose regimens.
Topics: Administration, Oral; Aged; Disopyramide; Drug Administration Schedule; Female; Humans; Injections, | 1976 |
Some aspects of the clinical pharmacology of intravenous disopyramide after myocardial infarction.
Topics: Arrhythmias, Cardiac; Blood Pressure; Disopyramide; Electrocardiography; Heart Rate; Humans; Injecti | 1976 |
The pharmacology of Norpace.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Atrioven | 1975 |
Effects of disopyramide phosphate on ventricular arrhythmias in experimental myocardial infarction.
Topics: Animals; Arrhythmias, Cardiac; Bundle of His; Disopyramide; Dogs; Electrocardiography; Female; Heart | 1976 |
Rapid infusions of bidisomide or disopyramide in conscious dogs: effect of myocardial infarction on acute tolerability.
Topics: Animals; Anti-Arrhythmia Agents; Disopyramide; Dogs; Dose-Response Relationship, Drug; Drug Toleranc | 1992 |
Inhibitory effect of moricizine on reperfusion induced tachyarrhythmias in rats--a comparison study with disopyramide and mexiletine.
Topics: Animals; Disopyramide; Heart; Hemodynamics; Male; Mexiletine; Moricizine; Myocardial Infarction; Rat | 1992 |
Metabolic, hemodynamic, and electrocardiographic responses to increased circulating adrenaline: effects of pretreatment with class 1 antiarrhythmics.
Topics: Adult; Analysis of Variance; Blood Pressure; Disopyramide; Electrocardiography; Epinephrine; Flecain | 1991 |
Mechanographic assessment of disopyramide in postinfarction patients.
Topics: Administration, Oral; Adult; Aged; Blood Pressure; Disopyramide; Electrocardiography; Heart Rate; He | 1991 |
Comparison of the electrophysiological effects of Org 7797, disopyramide, mexiletine and propafenone in anaesthetized dogs with myocardial infarcts.
Topics: Anesthetics; Animals; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Disopyramide; Dogs; Electr | 1991 |
Coupling interval-related effects of class I antiarrhythmic drugs, mexiletine, cibenzoline and disopyramide, on ventricular activation in canine myocardial infarction.
Topics: Animals; Anti-Arrhythmia Agents; Disease Models, Animal; Disopyramide; Dogs; Electric Stimulation; E | 1991 |
Binding of alfentanil to human alpha 1-acid glycoprotein, albumin and serum.
Topics: Adult; Aged; Alfentanil; Arthritis, Rheumatoid; Disopyramide; Female; Humans; Kidney Failure, Chroni | 1991 |
[Hemodynamic effects of disopyramide on postischemic and normal myocardium].
Topics: Animals; Cardiac Output; Disopyramide; Heart; Hemodynamics; Male; Myocardial Contraction; Myocardial | 1990 |
Antiarrhythmic drugs. Clinical pharmacology of the old and the new agents.
Topics: Acecainide; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sudden; Delayed-Action | 1985 |
Periodic changes in cycle length of ventricular tachycardia: a Wenckebach type exit block?
Topics: Bundle of His; Cardiac Complexes, Premature; Cardiac Pacing, Artificial; Disopyramide; Electrocardio | 1986 |
[Effects of disopyramide and quinidine on action potentials of canine ventricular myocardium and Purkinje fibers after myocardial infarction].
Topics: Action Potentials; Animals; Disopyramide; Dogs; Heart Conduction System; Heart Ventricles; In Vitro | 1987 |
Assessment of drug effects on spontaneous and induced ventricular arrhythmias in a 24-h canine infarction model.
Topics: Anilides; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disopyramide; Dogs; Electrocardiogr | 1987 |
Conversion from intravenous to oral slow-release disopyramide in acute myocardial infarction.
Topics: Adult; Aged; Blood Pressure; Delayed-Action Preparations; Disopyramide; Electrocardiography; Female; | 1987 |
Effects of intravenous disopyramide and quinidine on normal myocardium and on the characteristics of arrhythmias: intraindividual comparison in patients with sustained ventricular tachycardia.
Topics: Adult; Aged; Aged, 80 and over; Cardiac Pacing, Artificial; Coronary Disease; Disopyramide; Electroc | 1987 |
Disopyramide in acute myocardial infarction: problems with changing pharmacokinetics.
Topics: Aged; Biological Availability; Disopyramide; Female; Humans; Injections, Intravenous; Kinetics; Male | 1986 |
The usefulness of electrophysiological-pharmacologic studies in the long-term therapy of paroxysmal tachycardias.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Cardiomyopathies; Chromatogra | 1985 |
Disopyramide pharmacokinetics in patients with acute myocardial infarction.
Topics: Administration, Oral; Adult; Biotransformation; Creatinine; Disopyramide; Female; Hemodynamics; Huma | 1985 |
The acute changes in serum binding of disopyramide and flecainide after myocardial infarction.
Topics: Aged; Anti-Arrhythmia Agents; Blood Proteins; Disopyramide; Female; Flecainide; Humans; Male; Middle | 1985 |
Kinetics of disopyramide after intravenous infusion to patients with myocardial infarction and heart failure.
Topics: Aged; Disopyramide; Heart Failure; Humans; Kinetics; Metabolic Clearance Rate; Middle Aged; Myocardi | 1985 |
[Panel discussion: Evaluation of the antiarrhythmic drugs and current problems associated with their use in clinical practice (author's transl)].
Topics: Administration, Oral; Ajmaline; Aniline Compounds; Animals; Anti-Arrhythmia Agents; Cardiac Complexe | 1974 |